LINEAGE CELL THERAPEUTICS INC LCTX 深 滬
等待開盤 11-26 09:30:00 美东时间
1.735
-0.015
-0.86%
華盛通- 最 高1.81
- 今 開1.77
- 成交量 44.46万股
- 最 低 1.725
- 昨 收 1.75
- 總市值 3.96亿
- 52周最高 2.09
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.3651
- 委 比 -5.25%
- 總股本 2.28亿
- 歷史最高 3.132
- 量 比 0.48
- 振 幅 4.86%
- 歷史最低 0.3651
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
11-25 01:20
Lineage Therap Secures $5M Milestone Payment
Lineage Therap ( ($LCTX) ) has issued an update. On November 20, 2025, Lineage ...
11-25 01:08
Lineage Therap Sells 12 Million Shares to Janus
An update from Lineage Therap ( ($LCTX) ) is now available. On November 12, 202...
11-12 22:45
Lineage Cell Therapeutics shares are trading lower after the company reported mixed Q3 financial results.
Lineage Cell Therapeutics shares are trading lower after the company reported m...
11-07 22:17
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Lineage Therap (LCTX) Gets a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lineage The...
09-08 20:56
Lineage Cell Therapeutics Announces Launch Of A New Islet Cell Transplant Program Targeting Type 1 Diabetes
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the
09-08 20:01
Lineage And William Demant Collaborate Through Investment To Develop ReSonance For Hearing Loss
Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of development costs to be contributed by William Demant Invest
08-26 20:05
Update: Lineage Cell Therapeutics Q2 Adj. EPS $(0.07) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 159.26 percent. This is a 133.33 percent decrease over losses of $(0.03) per
08-13 04:04
